Cholinesterase inhibitors in dementia with Lewy bodies - A comparative analysis

International Journal of Geriatric Psychiatry

Volumn 22, Issue 9, 2007, Pages 890-895

  Bhasin, Mani ^a   Rowan, Elise ^a   Edwards, Keith ^b,c   McKeith, Ian ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b Alzheimer's Diagnostic and Treatment Center   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholinesterase inhibitors; Dementia with Lewy bodies; Donepezil; Galantamine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

AGED; ARTICLE; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; FEMALE; GALANTAMINE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 34648846451     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1759     Document Type: Article

References (21)

1. Aarsland D, Mosimann UP, McKeith IG. 2004. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17: 164-171.
2. Ballard CG. 2002. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 47: 64-70.
3. Coyle J, Kershaw P. 2001. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 49: 289-299.
4. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
5. Edwards K, Farlow M, Hake A, et al. 2004. An open label, 24-week, flexible dose trial to assess the safety and efficacy of galantamine in patients with dementia Lewy bodies. NeuroBiology of Aging 25(52): 21.
6. Fahn S, Elton RL. 1987. Unified Parkinson's Disease Rating Scale. In Recent developments in Parkinson's disease, Fahn S, Marsden CD, Goldstein M, Calne DB (eds). McMillan: New York; 153-163.
7. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
8. McKeith IG, Galasko D, Kosaka K, et al. 1996. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124.
9. McKeith I, Del Ser T, Spano P, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
10. McKeith I, Dickson D, Emre M, et al. 2005. Dementia with Lewy bodies: diagnosis and management: third report of the DLB consortium. Neurology 65(12): 1863-1872.
11. O'Brien KK, Saxby BK, Ballard CG, et al. 2003. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13: 231-239.
12. Perry EK, Haroutunian V, Davis KL, et al. 1994. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 5: 747-749.
13. Perry EK, Marshall E, Kerwin J, et al. 1990. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. Journal of Neurochemistry 55(4): 1454-2456.
14. Perry EK, Piggott MA, Johnson M, et al. 2003. Neurotransmitter correlates of neuropsychiatric symptoms in dementia with Lewy bodies. In Mental and Behavioral Dysfunction in Movement Disorders, Bedard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesperance P (eds). Humana Press Inc: Totowa, NJ; 285-294.
15. Samuel W, Caligiuri M, Galasko D, et al. 2000. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15(9): 794-802.
16. Shigeta M, Homma A. 2001. Donepezil for Aizheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Reviews 7: 353-368.
17. Thomas AJ, Burn DJ, Rowan EN, et al. 2005. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatric Psychiatr 20: 938-944.
18. Tiraboschi P, Hansen LA, Alford M, et al. 2000. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411.
19. Wilcock GK, Scott MI. 1994. Tacrine for senile dementia of Alzheimer's or Lewy body type. Lancet 344: 544.
20. Wilkinson D, Murray J. 2001. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 16: 852-857.
21. Zaccai J, McCracken C, Brayne C. 2005. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age & Ageing 34(6): 561-566.